Concepedia

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

Yutaka Seino, Maria Rasmussen, Milan Zdravković, Kohei Kaku

Diabetes Research and Clinical Practice · 2008 · 118 citations · 17 references

DOI

Concepts

References

17

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

David R. Matthews, J P Hosker, A. Rudenski et al. · Diabetologia · 1985 · 31K citations · Full text

, , +13

The pharmacokinetics of Norpace.

Aziz Karim · PubMed · 1975 · 555 citations

, , +6

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

Henrik Agersø, Lene Jensen, B. Elbrønd et al. · Diabetologia · 2002 · 503 citations · Full text

, , +5

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll, Milan Zdravkovic, T Le-Thi et al. · Diabetes Care · 2007 · 467 citations · Full text

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Kristine B. Degn, Claus Bogh Juhl, Jeppe Sturis et al. · Diabetes · 2004 · 424 citations · Full text